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Although circulating microRNAs (miRNAs) can modulate gene expression and affect immune system response, little is known
about their participation in age-associated frailty syndrome and sarcopenia. The aim of this study was to determine miRNAs as
possible biomarkers of age and frailty and their correlation with oxidative and inflammatory state in human blood. Three
inflammation-related miRNAs (miR-21, miR-146a, and miR-223) and one miRNA related with the control of melatonin
synthesis (miR-483) were analyzed. Twenty-two healthy adults, 34 aged robust, and 40 aged fragile patients were selected for
this study. The expression of plasma miRNAs was assessed by RT-qPCR; plasma cytokines (IL-6, IL-8, IL-10, and TNFα) were
analyzed by commercial kits, and plasma advanced oxidation protein products (AOPP) and lipid oxidation (LPO) were
spectrophotometrically measured. Fragile subjects had higher miR-21 levels than control subjects, whereas miR-223 and miR-
483 levels increased at a similar extend in both aged groups. All cytokines measured increased in aged groups compared with
controls, without differences between robust and fragile subjects. The fragile group had a TNFα/IL-10 ratio significantly higher
than robust and control groups. Aged groups also had higher AOPP and LPO levels than controls. Women presented higher
AOPP and LPO levels and increased expression of miR-483 compared with men. Positive correlations between miR-21 and
AOPP and between miR-483 and IL-8 were detected. The expression of miR-21 and the TNFα/IL-10 ratio were correlated
positively with the presence of frailty, which suggests that these markers can be considered as possible biomarkers for
age-related frailty.
1. Introduction
One reason that aging is emerging as a key policy issue is that
both the proportion and absolute number of older people in
populations around the world are increasing dramatically.
Aging is a global problem affecting both developed and
developing countries. According with the World Health
Organization report of 2015, the older adult population in
sub-Saharan Africa is expected to grow faster than anywhere
else, increasing from 46 million in 2015 to 157 million by
2050 [1]. In terms of life expectancy at birth, the EU is a
world leader, and according to “The 2015 Ageing Report” by
European Commission, the life expectancy at birth for males
is expected to increase by 7.1 years from 2013 to 2060 period,
reaching 84.8 in 2060 [2]. For females, it is projected to
increase by 6.0 years, reaching 89.1 in 2060. As a result,
the demographic old-age dependency ratio (people aged
65 or above relative to those aged 15–64) is projected to
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increase from 27.8% to 50.1% in the EU as a whole over
the mentioned period. Similar changes are expected in many
other countries.
Apart from the usual age-related diseases, progressive
loss of muscle mass and function associated with aging limits
the physical capabilities of the older population and increases
the cost of health care by the public health system. This
age-related muscle wasting has been termed sarcopenia.
The preliminary concept of sarcopenia as an age-related
loss of muscle mass and function [3] was updated in
2010 by the European Working Group on Sarcopenia in
Older People (EWGSOP) focus on a generalized loss of
muscle mass and strength with the risk of physical disability,
poor quality of life, and death [4].
Sarcopenia is one of the manifestations of frailty, a
clinical condition of aged adults that increases risk for poor
health outcomes including falls, disabilities, hospitalization,
and death [5]. Clinical features of frailty are related to
chronic inflammation associated to the age (inflammaging),
oxidative stress, mitochondrial dysfunction, insulin resis-
tance, aging-related loss of anabolic hormones, diminished
strength, and tolerance to physical activity [6]. The preva-
lence of frailty of adults aged 65 and older is 12% in the
USA, increasing up 25% in the group of 85 years or older
[7]. Similar data have been reported in other countries
including the European Union [2].
Circulating noncoding RNAs (miRNAs) are small RNA
molecules that, depending upon base pairing to mRNA,
mediate mRNA cleavage, translational repression, or mRNA
destabilization [8, 9]. miRNAs or miRs are involved in crucial
cellular processes, and their deregulation has been described
in different diseases, including aging, sarcopenia, and age-
related musculoskeletal impairments [10–12]. Due to the role
of some miRNAs to promote inflammation, changes in
expression of miRNAs throughout life, and their easily
measurement in blood, it is suggested that miRNAs may be
candidates for an early diagnosis of frailty in the elderly.
Thus, as a potential noninvasive method to study
frailty, we consider it worthwhile the determination of
some miRNA levels in blood and analyze whether changes
in circulating miRNAs correlate with oxidative stress and
inflammation during aging and frailty. We determined
miR-21, miR-146a, and miR-223, three miRNAs related
with inflammation, and miR-483, which is related with the
control of melatonin synthesis, the hormone with anti-
aging properties [13].
2. Materials and Methods
2.1. Participants. Control samples were collected from
healthy volunteers. Samples from frailty and nonfrailty aged
groups of subjects were obtained from the cohort of the
Toledo study for healthy aging, whose characterization was
published elsewhere [14]. The participants in the study were
classified into three groups: young healthy group (control),
aged healthy group (robust), and aged fragile group (fragile)
(Table 1). Informed consent was obtained from all subjects
and from the Hospital Ethical Committee, according to the
1983 revised Helsinki Declaration of 1975. The final study
was approved by the Andalusian Ethical Committee (ref.
CEEA: 462-CEEA-2013). The diagnosis of frailty in aged
population was based on the Fried criteria (weakness, low
speed, low physical activity, exhaustion, and weight loss)
[15]. As an indirect measurement of sarcopenia, a hand grip
strength test was used [16].
2.2. Assessment of Frailty and Physical Performance. The
Fried criteria used for diagnosis of frailty are described as
follows [15]: weakness is defined as the worse quintile of
maximum strength on the dominant hand adjusted for sex
and body mass index (kg/m2), strength was measured with
a Jaymar hydraulic dynamometer, according to the standards
of the Hispanic EPESE, weight was measured with a SECA
precision scale, and height was measured with a stadiometer
on a wall without a skirting board [17]. Physical performance
was assessed with the following criteria: (1) low energy,
subjects were classified as having “low energy” when they
provided a positive answer to any of the following two
questions from the CES-D (Center for Epidemiologic Studies
Depression Scale) [18]: “I felt that anything I did was a big
effort” and “I felt that I could not keep on doing things” at
least 3 to 4 days a week; (2) slowness, defined as the worse
Table 1: Characteristics of the studied subjects.
Item Control group Aged without frailty Aged with frailty
Number of subjects 22 34 40
Age 20.5± 2.4 76.6± 5.3 84.4± 5.6
Gender (male/female)
Male 19 (86%) 12 (35%) 13 (33%)
Female 3 (14%) 22 (65%) 27 (67%)
<80 years old (M/F) 0 24 (10/14) 8 (2/6)
≥80 years old (M/F) 0 10 (2/8) 32 (11/21)
Physical activity n.m. 79.69± 8.05 10.77± 2.76###
Physical dependence 0% 12%∗∗∗ 75%###
Hypertension 0% 38%∗∗∗ 32%∗∗∗
Age and physical activity are expressed as the means ± SEM. M/F: male/female; n.m.: not measured. ∗∗∗P < 0 001 versus the control group; ###P < 0 001 versus
aged without frailty.
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quintile in the three-meter walking speed test, adjusted for
sex and height according to the standards of the Short Phys-
ical Performance Battery [19]; and (3) weight loss, defined as
unintentional weight loss of 4.5 kg or more in the last year.
One point was assigned to each variable and built a score as
the sum of points for all of them. According to this score,
aged subjects were classified as nonfrail or robust (0 points),
prefrail (1-2 points), and fragile (≥3 points). For this study,
we used samples of robust and fragile patients only. The data
of physical activity of the patients were obtained with the
Physical Activity Scale for the Elderly (PASE). This question-
naire was specifically developed to assess the physical activity
in epidemiological studies in people≥ 65 years [20]. Physical
dependence was evaluated based on measures reflecting the
personal persuasion of need of help for the accomplishment
of activities of daily living. The information about the
presence of hypertension was based on medical diagnosis.
2.3. Samples. Blood samples (10mL) were collected from the
antecubital vein between 8:00 and 9:00 a.m. after 8–10 hours
of fasting. The samples were collected in vacutainer tubes
with EDTA-K2. Blood was centrifuged at 1900×g for
10min at 4°C, and plasma and erythrocytes were separated.
Aliquots of plasma were transferred into RNase-free micro-
centrifuge tubes and stored at −80°C until the assays were
performed. Once thawed, 250μL of all plasma samples
was centrifuged at 16000×g at 4°C for 10min to remove
cryoprecipitates. 100μL of plasma supernatants was used
for miRNA isolation.
2.4. Plasma miRNA Profiling and Data Analysis. Plasma
miRNAs were extracted using the miRNeasy Serum/Plasma
Kit (Qiagen, Werfen España, Barcelona, Spain) by following
the manufacturer’s instructions. Reverse transcription of
the microRNAs into cDNA was done with the TaqMan
MicroRNA Reverse Transcription Kit (Life Technologies,
Thermo Fisher Scientific, Madrid, Spain) and TaqMan
microRNA assays specific for miR-21, miR-146a, miR-223,
miR-483, and U6 (Applied Biosystems, Thermo Fisher
Scientific, Madrid, Spain) according to the manufacturer’s
recommendations. PCR was performed in 15μL reaction
mixtures using the MJ Mini Personal Thermal Cycler (Bio-
Rad Laboratories, S.A., Madrid, Spain). The samples were
subjected to thermal cycling parameters of 30min at 16°C,
30min at 42°C, and 5min at 85°C and then kept at 4°C.
Real-time PCR reaction was performed in a final volume of
20μL, containing 1.33μL of cDNA, 10μL of TaqMan Uni-
versal Master Mix II with no UNG (Life Technologies,
Thermo Fisher Scientific, Madrid, Spain), 7.67μL of RNase-
free water, and 1μL of TaqMan microRNA probe specific
for each examined microRNAs (Life Technologies). The
cycling conditions were as follows: initial denaturation at
50°C for 2 minutes, followed by enzyme activation at 95°C
for 10 minutes, and 40 cycles of 95°C for 15 seconds and
60°C for 1 minute. PCR was performed using an Agilent
Technologies Stratagene Mx3005P System (Life Technolo-
gies, Thermo Fisher Scientific, Madrid, Spain). All real-time
PCR reactions were performed in triplicate. After the reac-
tion, the threshold cycle values were determined using fixed
threshold settings. When the average of miRNA expression
was ≥35 Ct , it was not included in analysis. Data were ana-
lyzed using the SDS 2.3 and RQ Manager 1.2 software pack-
ages (Life Technologies), and relative gene expression was
generated using the 2−ΔΔCT method (ΔCt target gene−ΔCt
control gene). All miRNAs were calibrated against spike-in
control miR-39 (external control). As there is no consensus
on endogenous stable miRNAs in the circulation for nor-
malization and quantification of circulating miRNAs, the
expression levels were normalized both against U6 snRNA
(internal control) and against the average Ct of the control
group (general normalization) [21, 22].
2.5. Determination of Advanced Oxidation Protein Products.
Advanced oxidation protein products (AOPPs) were mea-
sured spectrophotometrically on a microplate reader. Sam-
ples were calibrated with chloramine-T solution that in the
presence of potassium iodide absorb at 340nm [23]. 200μL
of plasma diluted 1/5 in PBS, 10μL of PBS, and 20μL of
concentrated acetic acid were added to sample wells. The
standard curve was made with 10μL of 1.16M potassium
iodide, 200μL of chloramine-T solution (0–100nmol/mL),
and 20μL acetic acid. The absorbance of the reaction mixture
was immediately read at 340 nm on a microplate reader
against a blank containing 200μL PBS, 10μL potassium
iodide, and 20μL of acetic acid. The AOPP concentration
was expressed in nmol/mL of chloramine-T equivalents.
2.6. Determination of Lipid Peroxidation. Plasma samples
were thawed and centrifuged at 5000g x 5min at 5°C, and
200μL of the supernatants were used for lipid peroxida-
tion (LPO) measurement. For this purpose, a commercial
LPO assay kit that estimates both malondialdehyde and
4-hydroxyalkenals was used (Bioxytech LPO-586 assay kit,
Oxis Research, CA, USA). Absorbance was read at 586 nm,
and lipid peroxidation concentration was expressed in
nmol/mL [24].
2.7. Measurement of Plasma Cytokines. The Affymetrix’s
ProcartaPlex Simplex Kits refs EPX010-10213-901 for IL-6,
EPX010-10204-901 for IL-8, EPX010-10215-901 for IL-
10, and EPX010-10223-901 for TNFα (Labclinics, S.A.,
Barcelona, Spain) were used to profile expression of these
cytokines. The assay was performed according to the manu-
facturer’s instructions. Briefly, 50μL of working solution
containing multiple microbeads labeled with specific anti-
bodies against each cytokine was added into each well,
washed twice with 200μL of wash buffer, and filtered to
dryness. Then, 25μL thawed plasma aliquots diluted 1 : 4
with the specific LINCOplex sample diluent was added to
each well and incubated for 60min at room temperature.
After a wash step (twice) with 200μL wash buffer, the beads
were incubated with 25μL of the detection antibody cocktail
containing a specific antibody to each cytokine for 30min at
room temperature. The mixture was washed twice with
200μL wash buffer; the beads were incubated with 25μL of
the streptavidin-phycoerythrin solution for 30min at room
temperature and washed twice again. The beads were resus-
pended with 100μL of buffer and the concentration of each
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cytokine was determined using the array reader (Bio-Rad
Laboratories, Madrid, Spain). A parallel standard curve was
constructed for each cytokine. Cytokine levels were expressed
in pg/mL.
2.8. Statistical Analysis. Data were analyzed using SPSS
version 20.0 (WPSS Ltd., Surrey, UK), and graphs were
generated using GraphPad Prism 6 scientific software
(GraphPad Software Inc., La Jolla, CA, USA). Data were
assessed for normal distribution with the Shapiro-Wilk test,
and most of them do not have normal distribution. Nonpara-
metric tests (Mann–Whitney rank test) were used to examine
any differences among groups. Correlations between 2
parameters were assessed using simple linear regression.
Binomial logistic regression analysis was used to explore the
association between plasma miRNAs, oxidative biomarker
levels, and the presence of frailty. Results are displayed
as odds ratios (Exp B ) and 95% confidence intervals
(CI). Differences were considered statistically significant
at P values< 0.05. Data are expressed as means± standard
error of the mean (SEM).
3. Results
3.1. Characteristics of the Studied Subjects. Table 1 shows the
profile of the subjects of the study. The control group was
constituted by 22 healthy adults, 15 males, and 7 females,
with a mean age of 20.5± 2.4 years. Two groups of aged sub-
jects, robust and fragile, aged 76.6± 5.3 and 84.4± 5.6 years,
respectively, were also enrolled in the study. As expected,
fragile patients have a lower index of daily physical activity
and higher physical dependency than those robust patients.
Hypertension was present in a similar extent in both aged
groups of subjects.
3.2. Plasma miRNA Expression in Studied Samples. The
relative cycle threshold (Ct) for U6 small nuclear RNA was
used as an endogenous control for normalizing the respective
miRNAs Ct as previously described [22]. Because some are
concerned with the use of this method for circulating miR-
NAs, we also normalized with the average Ct of the control
group. Both normalization methods, however, yield similar
results and statistical differences between groups. Compared
with the control group, the robust group had higher expres-
sion of miR-146a, miR-223, and miR-483, while the fragile
group showed higher expression of miR-21, miR-223,
and miR-483 (Figures 1(a), 1(c), and 1(d)). So, except
for miR-21 in the robust group and miR-146a in the fragile
group, age courses with enhanced expression of miRNAs
were analyzed (correlation between miR-223 expression
and age (r = 0 359; P < 0 001) and between miR-483 expres-
sion and age (r = 0 2461; P < 0 01) was significant, data not
shown). Women had increased expression of miR-483 com-
pared with men (2.12± 1.18 versus 1.44± 0.99, P < 0 001,
data not shown). Thus, the results from both methods of
normalization guarantee the identification of these miRNAs
in our samples, and then, we used normalization for U6. Pos-
itive correlations between miR-223 and miR-21 (r = 0 608,
P < 0 001) and between miR-483 and miR-146a (r = 0 504,
P < 0 001) were found (Figures 1(e) and 1(f), respectively).
3.3. Markers of Inflammation and Oxidative Stress in Studied
Samples. Regarding the inflammatory markers, here mea-
sured, we found that IL-6, IL-8, and IL-10 levels increased
significantly in both aged groups compared with those in
the young control (Figures 2(a)–2(c)), with a trend to display
higher levels of IL-8 in the fragile group. In addition, TNFα
becomes significantly higher in the fragile group compared
with that in control and robust ones (Figure 2(c)). Regard-
ing inflammatory/anti-inflammatory balance measured by
the index TNFα/IL-10, we detected significant difference
between fragile subjects and controls, as well as between
fragile and robust subjects (Figure 2(e)). No differences
between men and women were detected in the levels of the
cytokines measured. Because of the connection between
miRNAs and inflammation, we next studied the existence
of any correlation between these miRNAs and proinflamma-
tory cytokines. Our data show only positive correlation
between miR-483 and IL-8 (r = 0 430, P < 0 05) (data not
shown). As expected, age was accompanied with increased
oxidative stress, which is reflected in significantly higher
levels of LPO and AOPP in plasma of all aged patients com-
pared with youngers (Figures 3(a) and 3(b)). No significant
differences were found between aged robust and fragile
groups. Gender comparison of plasma levels of LPO and
AOPP reported that women have significantly higher levels
of these biomarkers than men (Figures 3(c) and 3(d)). Addi-
tionally, we found that miR-21 and AOPP correlated
significantly (r = 0 251, P < 0 05) (Figure 3(e)). Logistic
regression analysis suggested that the expression of miR-21
and index TNFα/IL-10 correlates positively with frailty
(Exp B = 1 423, 95% CI: 1.079–1.878, P = 0 013 for miR-21
and Exp B = 2 433, 95% CI: 1.019–5.810, P = 0 045 for
TNFα/IL-10).
4. Discussion
We present data that support that oxidative stress and
cytokines, as well as subclinical inflammation, measured
through miRs (miR-223 and miR-483), increase with age.
Also, miR-21 become significantly higher in the group of
fragile patients. We show here the association between
miR-21 with frailty and AOPP and between miR-483 with
frailty and IL-8; moreover, index TNFα/IL-10 was signifi-
cantly elevated in the fragile group. These results point to
the utility and feasibility of the determination of miRNAs
together with parameters of inflammation and oxidative
stress in a routine blood analysis to detect early signs of frailty
during aging.
It has been suggested that low miR-21 expression is
related with a healthier aging [25]. Different mechanisms of
action of miR-21 in age have been reported. Circulating
miR-21 can bind to toll-like receptors (TLRs) in surrounding
immune cells, leading to NF-κB pathway activation and
increased secretion of proinflammatory cytokines including
IL-6 and TNFα [26]. Moreover, miR-21 directly modulates
TGF-β signaling by targeting the TGF-βR2 in different






























































































































Figure 1: miRNA levels in control and aged groups (a)–(d). Relative expression of these miRNAs was calculated using the 2−ΔΔCt method.
The expression levels were normalized against U6 snRNA and against the average of the control group (Ct , general normalization). Data
are presented as means± SEM. ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001 versus the control group. Regression and correlation analysis with
relative expression of miRNAs, calculated using analysis of the Spearman correlation coefficient. Only those miRNAs that had significant
correlation are shown (e) and (f). C: control group; R: robust group; F: fragile group.
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cellular models. This signaling pathway can interconnect
inflammation, senescence, and cancer [27]. The increase in
serum miR-21 in response to an acute exhaustive exercise
in congestive heart failure patients further supports its
relationship also with muscle condition and, thus, sarcopenia
[28]. Here, we report a significant increase in plasma levels of
miR-21with frailty, supporting its relation with inflamma-
ging and age-related diseases.
Regarding miR-146a and unlike miR-21, the former
increase with age but not with frailty. miR-146a/b is a com-
ponent of a negative feedback loop that downregulates the
levels of IRAK1 by repressing TNF receptor-associated factor
6 (TRAF6) and interleukin-1 receptor-associated kinase 1
(IRAK1) expression [29]. An upregulation of miR-146a in
cells with high senescence-associated secretory phenotype
(SASP) leads to increase IL-1α levels enhancing IRAK1 and
NF-κB-dependent production of IL-6, IL-8, and also miR-
146a/b [30]. Hence, miR-146a can prevent an excessive
production of inflammatory mediators, thus limiting some
of the potentially deleterious effect of SASP [30]. Our results
showed that miR-146a was lower in fragile subjects that in
robust aged subjects, which may trigger the proinflammatory
pathway. In fact, fragile patients tend to have higher levels of
IL-8 and high levels of TNFα than healthy aged subjects.
Initially described as a key modulator of hematopoietic
lineage differentiation, miR-223 is one of the most abundant
miRNAs in plasma. miR-223 regulates the pathways related















































































Figure 2: Plasma levels of IL-6, IL-8, TNFα, and IL-10 in control and aged groups of subjects ((a)–(d)). TNFα/IL-10 ratio in the three
studied groups (e). Data are presented as means± SEM. ∗P < 0 05, ∗∗P < 0 01 and ∗∗∗P < 0 001 versus the control group. #P < 0 05
versus the robust group.
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include insulin-like growth factor 1 receptor (IGF-R1), IKKα,
STAT3, FOXO1, NLRP3, and Roquin, and it may induce the
activation of NF-κB in macrophages during their differentia-
tion [29]. Circulating miR-223 has been positively associated
with inflammation and fibrosis muscle-deficient mice [31].
Our results shown that miR-223 expression increased in both
groups of aged patients, and thus, miR-223 could be consid-
ered a biomarker of aging but not of frailty. This assumption
coincides with recent investigation of the epigenetic network
involved in human aging [32]. Nevertheless, newest findings
suggest that miRNAs do not act individually but rather exert
a cooperative control over different signaling pathways. Here,
we found a positive correlation between miR-21 and miR-
223. Whereas both of them are related with aging, the
former is also related with frailty and AOPP. Thus, miR-21











































































Figure 3: Lipid peroxidation (LPO) and advanced oxidation protein product (AOPP) levels in plasma of subjects of three studied
groups ((a) and (b)). LPO and AOPP levels in plasma were also classified according to gender ((c) and (d)). Data are presented as
means± SEM. ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001 versus the control group. Correlation analysis between miR-21 relative expression
and AOPP levels (e), calculated using analysis of the Spearman correlation coefficient. C: control group; R: robust group; F: fragile group.
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With regard to miR-483, different targets have been
described. Clokie et al. demonstrated that miR-483 extracted
from the rat pineal gland act as suppressor of arylalkylamine-
N-acetyltransferase (aanat) mRNA expression, the key
enzyme in melatonin synthesis [33]. High levels of miR-483
suppress N-acetylserotonin production, the melatonin pre-
cursor, leading to a reduction in melatonin synthesis. Our
data showed that miR-483 correlated with IL-8 and its
expression levels significantly increased with age. Since
melatonin production decays with age, the increased expres-
sion of miR-483 in aged patients could underlie the age-
dependent melatonin decay. Nevertheless, this affirmation
requires further confirmation because we did not measure
the levels of melatonin in the groups of subjects here studied.
Human aging can be considered as a complex process
that combines inflammation and oxidative stress. In our
study, we found a significant increase in the levels of the
proinflammatory cytokines IL-6, IL-8, and TNFα with age,
Moreover, some studies proved that elevated levels of TNFα
can increase muscle catabolism by suppressing the Akt/
mTOR pathway [34]. The tendency to increase IL-6, IL-8,
and significantly high levels of TNFα in the group with frailty
here reported, as well as increased inflammatory/anti-inflam-
matory balance measured by the index TNFα/IL-10, suggests
a role for these cytokines in muscle deterioration. Together
with inflammation, we report here the increase in LPO and
AOPP levels, reflecting the lipid and protein oxidative
damage. Again, these ROS did not show differences with
frailty, although women have significantly higher levels of
LPO and AOPP than men.
The use of different animal models for the study of
changes in aged muscle confirms that circulating miRNAs
indicate that while muscle and serum have distinct age-
related changes inmiRNA expression, somemiRNAs showed
the same directionality in expression changes [35]. Together,
our data suggest a relationship between c-miRNAs and
aged patients with and without frailty. Elevated levels of
miR-21 in frailty indicate an activation of innate immunity
associated with age, and it suggests miR-21 as a biomarker
of human muscle frailty. On the other hand, the reduction
in miR-146a levels in frailty can promote NF-κB-dependent
inflammation. The increased expression of circulating miR-
483 in the experimental group may contribute to the
decreased production of melatonin due to age. All these
changes are accompanied by increased levels of inflammatory
and ROS markers, indicating the presence of chronic inflam-
mation associated with age. Women, who have increased
AOPP, LPO, and miR-483 compared with men, can be
considered as the population most vulnerable to frailty.
5. Summary and Conclusions
We confirmed that aging and frailty are companied with
higher oxidative and inflammation states, such as increasing
expression of c-miR-21, c-miR-223, and c-miR-483, reflect-
ing the changes that occur at the molecular level in the
aging process.
Our results point that the miR-21 and TNFα/IL-10 ratio
may be considered as possible biomarkers for age-related
frailty. Enhanced understanding of alterations in c-miRNA
expression with aging and in different pathological condition
may result in a relevant diagnostic tool and offers more
information on mechanisms involved in the aging process.
Detection and identification of stable miRNAs in blood has
opened a new possibility in systemic biomarker research
directed at improving clinical diagnosis and prognosis.
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